Clinical Trials Logo

Clinical Trial Summary

The investigate the efficacy and safety of combined 'cryo-immuno-therapy' versus intralesional tuberculin purified protein derivative (PPD) antigen immunotherapy alone for multiple common warts


Clinical Trial Description

Common warts are benign skin lesions caused by the human papillomavirus (HPV). The dorsal surface of the hands and fingers are the main predilection sites. Cryotherapy is frequently used to eradicate common warts via necrotic destruction of HPV-infected keratinocytes or by inducing of an effective cell-mediated immune response. However, the cure rates of cryotherapy are only around (44-47%) .

Intralesional antigen immunotherapy represents a promising therapeutic approach for the treatment of different types of warts, particularly if multiple and/or recalcitrant.

The investigate the efficacy and safety of combined 'cryo-immuno-therapy' versus intralesional tuberculin purified protein n immunotherapy alone for multiple common warts.

Although intralesional immunotherapy - compared to conventional therapeutic methods - has been generally along with better outcome, lower incidence of side effects and less recurrence, it is not still approved as a standard method of treatment in patients with wart , because the majority of available studies are open-labeled and randomized, placebo-controlled trials are very scarce.

The immune system plays an important role in the spontaneous resolution of warts. The immune mechanisms against HPV include the development of cell-mediated immune response with activation of T helper1 (Th1) lymphocytes resulting in long-term immunity . Stimulation of the immune system would clear warts in other locations, eliminating the need for the local treatment for each individual wart .

Multiple studies support the use of intralesional PPD injection as an effective and valuable treatment option due to its systemic effect, especially for patients with multiple warts, with the benefit of clearance of both treated and distant warts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04288817
Study type Interventional
Source Assiut University
Contact Hiba Abdullah
Phone 01021432461
Email hibaalshaaby7@yahoo.com
Status Not yet recruiting
Phase Phase 3
Start date March 1, 2020
Completion date May 1, 2021

See also
  Status Clinical Trial Phase
Suspended NCT01796795 - Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients Phase 2
Completed NCT03687372 - Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Completed NCT03691831 - A Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT05115669 - Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts N/A
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Active, not recruiting NCT05896215 - OM202JP Clinical Study of KNP2002 Phase 2
Completed NCT03278028 - A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts Phase 2
Completed NCT03812510 - Safety Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Recruiting NCT05799157 - Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts Phase 2
Recruiting NCT06214559 - Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. N/A
Recruiting NCT03977753 - Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts Phase 4
Completed NCT03210337 - A Phase2 of A-101 Topical Solution in Subjects With Common Warts Phase 2
Completed NCT03183765 - Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Phase 4